Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire

N/ACompletedNCT01917175

ANRS, Emerging Infectious Diseases511 enrolled

Overview

Set-up of a biobank for patients with an estimated date of infection seroconverters: store plasma and cells samples at initial contact and during follow-up for future analysis and analysis in international collaborative cohort seroconverters.

Study Type

OBSERVATIONAL

Enrollment

511

Conditions

HIV Infection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients included in the last Primo-CI ANRS 1220 protocol * All HIV infected individuals diagnosed during a blood donation with an estimated date of HIV seroconversion that will respect the following criteria: (i) age ≥18 (ii) HIV-1 or HIV-1+2 infected, (iii) HIV-seronegative at the preceding donation; (iv) who returned to the clinic to be informed of their HIV test result (v) with an HIV serology confirmed with two specific tests in two different laboratories (vi) who have never received ART for curative purpose * informed on study objectives and have a signed informed consent. Exclusion Criteria: * Patient living outside of Abidjan

Locations (2)

Centre Médical du Suivi des Donneurs de Sang (Blood Bank Medical Centre)

Abidjan, Côte d’Ivoire

Centre National de Transfusion Sanguine (National Blood Transfusion Centre)

Abidjan, Côte d’Ivoire

Outcomes

Primary Outcomes

Natural history of HIV infection in Sub-Saharan Africa

Plasmatic HIV viral load and CD4 measured every six months and incidence of morbidity events associated with AIDS

Time frame: 12 months after ART initiation

Secondary Outcomes

Estimate the probability of disease progression after HIV seroconversion

Disease progression will be estimated with CD4 cell loss and time from seroconversion to clinical AIDS, death and antiretroviral therapy initiation

Time frame: 12 months after ART initiation

Evolution of markers of HIV infection and immunity

CD4 count, immune activation, plasma HIV-RNA intracellular, HIV-DNA

Time frame: 12 months after ART initiation

Viral genetic diversity description

biomolecular analysis of HIV-1

Time frame: Inclusion (J0)

Primary resistance to antiretroviral treatment

Frequency of primary resistance to antiretroviral treatment (genotyping)

Time frame: Inclusion (J0)

Metabolic and lipodystrophic disorders

Metabolic analysis (Total Cholesterol, HDL and LDL, Triglycerides) and lipodystrophia measurements

Time frame: 12 months after ART initiation

Incidence of pregnancies

Occurence of pregnancies

Time frame: 12 months after ART initiation

T lymphocytes activation and evolution in seroconverters

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.